Publication: Reassuring humoral and cellular immune responses to SARS-CoV-2 vaccination in participants with systemic sclerosis

Benoit JM, Breznik JA, Huynh A, Cowbrough B, Baker B, Heessels L, Lodhi S, Yan E, Bhakta H, Clare R, Nazy I, Bramson JL, Larché MJ, Bowdish DM. Reassuring humoral and cellular immune responses to SARS-CoV-2 vaccination in participants with systemic sclerosis. Immunol Lett. 2024 Sep 19;270:106929. doi: 10.1016/j.imlet.2024.106929. 

Below is a Bluesky thread that summarizes and explains our manuscript. Click here to read it on Bluesky.

New publication alert! “Reassuring humoral and cellular immune responses to SARS-CoV-2 vaccination in participants with systemic sclerosis” Read on to learn why we did this study and why it is important. 1/n https://www.sciencedirect.com/science/article/pii/S0165247824001032?via%3Dihub

https://bsky.app/profile/msmacrophage.bsky.social/post/3l5zdipjxwe2o

Systemic Sclerosis(SSc) is a rare autoimmune disorder that causes fibrosis of the organs. Because it is caused an immune system gone awry, patients and their doctors were concerned that their immune systems might not respond to the vaccine and leave them less protected 2/n

Because SSC is an autoimmune condition, people generally take immunosuppressive drugs, which can also lead to lower vaccine responses and higher risk of infection. We investigated whether antibody or T cell responses to vaccination were affected in SSC. 3/n

Good news! People with SSC made the same amount of antibodies to the receptor binding domain of the Spike protein (i.e, the bit of the virus that the virus uses to get into us) after their second, third, and fourth SARS-CoV-2 vaccinations. 4/n

More good news! T cell responses to vaccines are thought to help with severe disease and may offer some cross-variant protection. Following the second, third, and fourth SARS-CoV-2 vaccinations, participants with SSc had T cell responses = those without SSC. 5/n

For the immunology geeks: People living with SSc have elevated levels of serum cytokines associated with T cell differentiation. Could this change Th1/2/17/reg mix posts vaccination? Nope. 6/n

Caveat#1: This is a small study (because a rare disease) and we couldn’t investigate all the different drugs that people are on. For more info on how drugs affect vaccination responses see our other studies 7/n https://acrjournals.onlinelibrary.wiley.com/doi/full/10.1002/acr2.11697

Caveat #2: This is very much a comparison of the quantity of immune responses, not the quality. There could still be qualitative differences in immune responses that we didn’t catch but… 8/n

…even though there is very little data on whether SSC is associated with higher infection risk or poorer outcomes what little exists doesn’t find a massive difference compared to the general population 9/n https://acrjournals.onlinelibrary.wiley.com/doi/full/10.1002/acr.25226

Take home message #1: Participants with SSc mount similar responses to SARS-CoV-2 vaccination as controls who do not have autoimmune conditions. 10/n

Take home message #2: Many ppl with autoimmune conditions are afraid that vaccination is unsafe for them because they know their immune system is a bit wonky. It is not the disease that affects immune responses, rather it’s some, not all, drugs at some, not all, doses. 11/n

Thanks to emerging leader & 1st author Jenna Benoit (graduating & looking for a job next year – hint), rheumatologist extraordinaire, Dr. Maggie Larche, cellular immunologist Dr. J. Breznik & J Bramson, team Antibody (Nazy, Huynh) & with special thanks to…..12/n

….our participants. People with SSC often have skin changes which makes blood draws especially hard. Thank you for your commitment to our study and huge props to our exceptional phlebotomist/RC Braeden Cowbrough – our unsung hero. 13/n Fin.

Publication: “Monocyte-driven inflamm-aging reduces intestinal barrier function in females”

Click here to access: Monocyte-driven inflamm-aging reduces intestinal barrier function in females published in Immunity and Ageing, September 2024.

This publication by former PDF, Dr Candice Quin and team, discovers that inflammatory markers and gut permeability increase with age, but the leaky gut seems to be a female specific phenomena in both mice and humans.

Bluesky explainer thread below and here https://bsky.app/profile/msmacrophage.bsky.social/post/3l5ethyexgp2u

New publication alert! “Monocyte-driven inflamm-aging reduces
intestinal barrier function in females” by lead author Dr Candice Quin @uniofaberdeen.bsky.social. Read on for some surprising insights into sex differences in aging, the microbiome, inflammation, and the ‘leaky gut’ hypothesis….1/n

With age levels of inflammatory mediators (cytokines, CRP, & others) increase in the blood and tissues. This is often called ‘inflamm-aging’, and higher than age-average levels of these mediators are associated with chronic disease, frailty, and other age-associated ills. 2/n

Men & women age differently (‘men die quicker, women live sicker’)so it stands to reason they might ‘inflam-age’ differently, but very few studies on aging investigate sex differences in the aging trajectory. We looked at cellular & soluble inflammatory markers and saw sex differences! 3/n

We were surprised by the magnitude of sex differences but immunology is literally one of the worst disciplines when it comes to reporting by sex https://elifesciences.org/articles/70817
By why do we ‘inflamm-age’ in the first place? Might the mechanisms of inflamm-aging differ by sex 4/n

One of the major theories is that with age a dysbiotic microbiota causes the gut to become leaky (alternatively, the gut gets leaky with age and this alters the microbiota). Bacterial products leak out and cause inflammation. We’ve published in mice, others in other model organisms 5/n https://www.cell.com/cell-host-microbe/fulltext/S1931-3128(17)30112-9?elsca1=etoc&elsca2=email&elsca3=1931-3128_20170412_21_4_&elsca4=Cell%20Press

Evidence for the ‘leaky gut’ hypothesis is weak in healthy humans (despite what the probiotic industry might say). Leakiness is generally found in people who have comorbidities, or are frail so we looked at healthy/non-frail male (41) females (54) btw 20-102 yrs and were surprised to find…6/n

…that women appeared to have leakier guts over the life course (as measured by the serum marker zonulin- imperfect), and only women had evidence of an age-associated increase in the bacterial product LPS in their serum. Could the leaky gut hypothesis be female specific? 7/n

Human studies are observational so we turned to mice to understand the chain of causality. Old female, but not male, mice did indeed have leakier guts and this seemed to be caused by TNF produced by the elevated number of circulating inflammatory monocytes. 8/n

Tl;dr The age-related leaky gut -> increased circulating bacterial products -> systemic inflammation hypothesis may only be true in females! (also – always investigate sex in your research) 9/n

Why? Well the female gut changes dramatically during pregnancy to increase nutrient absorption – perhaps that is why women seem to have more permeability over the life-course. We are doing some cool ongoing studies in vitro looking at male vs female monocytes ability to break the gut barrier. 10/n

Caveats: This was a non-frail, mostly white population – aging & immunology studies show tremendous differences by location so needs to be reproduced. Gut permeability measures were done by looking at serum markers – easy on the participant but indirect at best. 11/n

Thanks to the whole (unfortunately not on Bluesky team)! This was an incredibly fun and challenging project to work on but has cemented my commitment to considering sex in all the research we do. 👩‍🔬🧪🦠🚨 12/12

Publication: “Immunomodulatory drugs have divergent effects on humoral and cellular immune responses to SARS-CoV-2 vaccination in people living with rheumatoid arthritis”

Jenna Benoit (PhD candidate) has published her first, first author paper characterizing how immune responses to vaccination differ in people living with rheumatoid arthritis. We found some interesting new drug-immune interactions.

See the full paper here.

See thread here: https://bsky.app/profile/msmacrophage.bsky.social/post/3kh2uswvqtm2u

or below….

New paper alert! @jennabenoit.bsky.social and team studied COVID-19 vaccinations in people living with rheumatoid arthritis who are on immunosuppressive drugs and found some interesting, and to our knowledge, unknown effects of specific drugs 1/n

Almost all studies of vaccine immunogenicity (i.e., how strong an immune response is to a vaccine) focus on antibody responses. Measuring the amount of antibodies produced is cheap and (relatively) easy; however, in the Omicron-era these are less predictive of protection than you might think 2/n

When investigating anti-receptor binding domain (RBD) antibodies @jennabenoit.bsky.social and team found that -unsurprisingly- people living with RA and men had lower antibody responses (men have lower antibody responses to vaccination in general), and people with COVID had higher responses (i.e., that hybrid immunity you’ve heard so much about) 3/n

What caused these lower antibody responses? DMARDs (disease modifying anti-rheumatic drugs),and anti-TNF were not associated with lower antibody levels, the effect of steroids was not significant, but costimulation inhibitors reduced antibody levels 4/n

Important caveat: The effect of co-stimulation inhibitors was about the same as being a biologic male, so whether this reduction is associated with increased risk of infection or not is not something we can comment on 5/n.

We didn’t see an effect of drugs on neutralizing antibodies (i.e., antibodies that bind the virus really well and prevent it from entering us), but we did not have enough people on some of the drugs to really investigate this 6/n.

My favourite part: CD4+ and CD8+ T cell responses to vaccination are much, much harder to measure (each dot on the graph costs about $350 and 3+ hrs of time – hence the ‘team’ I keep mentioning) but we know that they are important for preventing infection.7/n

We found that people living with RA had lower CD4+ T cell responses (= ‘helper’ cells that support many aspects of the immune response to infection & vaccination), those who had had COVID were higher – more of that hybrid immunity you’ve heard about. 8/n

BUT even though we had a small number of people on JAK inhibitors, those who were on them had markedly lower CD4+ responses. The effect of co-stimulation inhibitors was not as apparent – but again low numbers of participants so hard to say. 9/n

Speculative side note: We use influenza vaccine as a control. Everyone has had exposure as kids so this measures a memory response made prior to having been vaccinated. Co-stim inhibitors don’t affect influenza but JAK inhibitors do – therefore no defect in pre-drug immune responses? 10/n

CD8+ T cell responses (‘killers’ of virus infected cells), were higher in men (previously known), and didn’t seem to be lower in most drugs, except maybe steroids. 11/n

Caveats: Our study was small and due to the fact we were measuring 1,2,3 doses, we were recruiting fast and furious and didn’t capture as many people on some of the drugs as we would have liked,so all results need to be replicated. 12/n

Clinical relevance: Some of these drugs are associated with increased risk of severe disease (see text for references) and by learning which aspects of the immune response they affect, we learn which aspects of the immune response are required for a successful vaccine. 13/n

Deepest appreciation for our research participants, the Canadian Arthritis Patient Alliance (see website for talks on this topic), the SUCCEED investigator team, our technical staff, fundign from the Public Health Agency of Canada, and you for reading to 14/n

Congratulations to Pat Schenck & Jessica Breznik on winning the Farncombe Research in Progress Awards!

Jessica Breznik (co-supervised by Dr. Deborah Sloboda) won the “Best Presentation by a PhD student” while Pat Schenck (co-supervised by Dr. Mike Surette) won runner up!  What a wonderful tribute to their skills in both research and communication – well done!

Congratulations to Sara Makaremi (PhD candidate) for winning the Gerald T Simon Award for her microscopy!

Congratulations Sara for winning the Gerald T Simons award for her presentation at the Microscopical Society of Canada and Microscopical Society of America (M&M2018) in Baltimore.

To read her award winning abstract, click here.

 

Congratulations to Dessi Loukov on successfully defending her PhD!

Congratulations to the newly minted Dr. Loukov on successfully defending her thesis entitled “Age-Associated Inflammation impairs Myeloid Development and Monocyte & Macrophage Function”!

The newly minted Dr. Loukov drinks from the chalice.

Dessi celebrates her thesis defence with one of her mentors Dr. Mark McDermott.

Two doctors.

Alumnus Update: Melissa Ling, Bowdish lab undergraduate, accepted to Yale University.

Congratulations to Melissa Ling, a former Bowdish lab undergraduate thesis student who was accepted to Yale University’s Masters of Medical Science in the Physician Associate Program. This prestigious program has a 3.6% acceptance rate so we are very proud of her.

Best of luck Melissa!

Pictured here in her Bowdish lab days.

Kyle Novakowski is the Bowdish lab’s newest PhD!

Kyle Novakowski successfully defended his thesis “IDENTIFICATION AND  FUNCTIONAL CHARACTERIZATION OF CONSERVED RESIDUES AND DOMAINS IN THE MACROPHAGE SCAVENGER RECEPTOR MARCO”  to become the Bowdish lab’s 4th PhD student. He’ll be joining Turnstone Biologics as a PhD scientist. We wish him very well in his future endeavours. Congratulations Dr. Novakowski!